Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.49 |
| ▸ | CCR1 | P32246 | 2/20 | 0.48 |
| ▸ | CCR3 | P51677 | 2/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.45 |
| ▸ | PRCP | P42785 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036380 | 1.00 | MEN1 (0.54) | MEN1KMT2ASIGMAR1ACKR3CCR1 | |
| SCHEMBL4031775 | 0.83 | SIGMAR1 (0.60) | MEN1KMT2ASIGMAR1CCR1CCR3 | |
| SCHEMBL4032891 | 0.81 | SMN1; SMN2 (0.60) | MEN1KMT2ASIGMAR1CCR1CCR3 | |
| SCHEMBL4213798 | 0.75 | MEN1 (0.48) | MEN1KMT2ASIGMAR1CCR1CCR3 | |
| SCHEMBL4031536 | 0.74 | TSHR (0.58) | MEN1KMT2ASIGMAR1CCR1CCR3 | |
| SCHEMBL4031280 | 0.74 | TSHR (0.58) | MEN1KMT2ASIGMAR1CCR1CCR3 | |
| SCHEMBL4037988 | 0.73 | SIGMAR1 (0.55) | MEN1KMT2ASIGMAR1CCR1CCR3 | |
| SCHEMBL4032532 | 0.71 | ATM (0.55) | MEN1KMT2ASIGMAR1CCR1CCR3 | |
| SCHEMBL4032329 | 0.71 | KMT2A (0.49) | KMT2ACCR3 | |
| SCHEMBL4031705 | 0.71 | SMN1; SMN2 (0.72) | KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | claimed |
| EP-1212299-B1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LTD (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | MERRILL LYNCH CAPITAL, A DIVISION OF MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC. AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| US-6903085-B1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | ASTRAZENECA, AB (CH) | 2005-06-07 | — | — | US | disclosed |
| EP-1212299-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca UK Limited (GB) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001014333-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LIMITED (GB) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR3 | MEN1 4130/4885KMT2A 2580/4885SIGMAR1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.